Management of menorrhagia

Click here to load reader

download Management of menorrhagia

of 24

description

Management of menorrhagia according to latest guidelines. It is just summary of the latest guidelines.

Transcript of Management of menorrhagia

  • 1.Amalina Mohd Daud 0917298 Management of Menorrhagia

2. Outline Pharmacological treatment Surgical treatment Lifestyle modifications 3. Pharmacological treatment Choices 1. Hormonal treatment 2. Non-hormonal treatment 4. HORMONAL TREATMENTS 5. LNG-IUS Vertical stem: release daily doses of 20 micrograms of LNG Effects: -prevent endometrial proliferation -thicken cervical mucus -suppress ovulation Cost effective when compared with other hormonal and non hormonal treatments Reduction of MBL between 71-96% -benefit seen after 6 months 6. COCP Contain estrogen and progestogen in combinations Act on HPO axis to suppress ovulation and fertility -cause withdrawal bleeding Reduces MBL by 43 % - Greater than naproxen - Lesser than danazol and tranexamic acid Less benefit with higher cost 7. Oral Progestogen Progesterone -hormone produced during luteal phase -cause secretory transformation of endometrium bleeding when levels fall Reduction of MBL by 84% (93% : LNG) Requires long course regimen 8. Danazol Anti-estogenic and anti-progesteronic activity -antiproliferative to endometrium -anovulatory by preventing GnRH at pituitary Reduce MBL by 50% Significant androgenic side effects -weight gain -acne -hirsutism -voice changes Reversible with treatment cessation 9. GnRH-analogues Synthetic peptide that act like a natural GnRH but with longer biological half life Action 1. Flare effect -increase FSH and LH 2. Profoung hypogonadal effect - after 10 days downregulation No follicular development, estrogen production, no ovulation, no progeterone, no menses Treatment 1. Hormonal sensitive cancer -breast cancer, prostate cancer 2. Estrogen dependant lesion - leiomyoma, endometriosis Reduces MBL but with high adverse effects 10. Non-hormonal treatments 11. Tranexamic acid Competitive inhibitor of plasminogen activator -antifibrinolytic agents Menorrhagia -Reduced breakdown of fibrin preformed clot in spiral endometrium arterioles reduce MBL Reduce MBL by 34-59% Cost effective when compared with other NSAIDS and no treatment -not when compared with LNG-IUSHowever, -not reduce dysmenorrhea -not a contraceptive -not regulate cycles Dosage: 1g ( 2 tablets) 3-4x daily from onset of bleeding up to 4 days 12. NSAIDs Reduce prostaglandin synthesis by inhibiting COX Prostaglandin: - Inflammatory response - Pain pathways - Uterine cramps - Uterine bleeds Reduces MBL 20-49% but tranexamic acid and danazol reduces MBL greater -better AE profile than danazol Less cost effective than LNG and tranexamic acid Treatment of dysmenorrhea However, - Not contraceptions - Not to be used in bleeding disorders 13. Recommendation for Pharmaceutical Approach 14. Recommendations Considered in - no structural or histological abnormalities - fibroid